Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease Therapeutics and Diagnostics: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Alzheimer's Disease Therapeutics and ...

Biogen and Eisai are also running another phase 3 clinical study – AHEAD 3-45 – which is evaluating intravenous lecanemab in people with preclinical Alzheimer's and elevated amyloid levels.

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Iterative Health, a healthcare technology and services company partnering with physicians to advance gastrointestinal care, will present five abstracts at the European Crohn's & Colitis Organization ...

Bruker Corporation today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also ...

Leqembi, from Japan's Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition. The delay in cognitive decline ...

The dementia drug 'Leqembi', developed jointly by Japanese pharmaceutical company Eisai and U.S. Biogen, can be prescribed only after confirming the suitability of the patient using PET-CT scans.